The DOI matches its Crossref record.
Endothelial cell proliferation as a novel approach to targeting tumour therapy
Open accessAbstract
THE proliferation rate of vascular endo-thelial cells in tumours exceeds that in most adult normal tissues by a very large factor, often greater than 20 (Figure). This enormous differential offers a potential route for aiming tumour therapy at solid tumours by means of a targeted systemic toxin, with little risk of damage to most of the normal tissues. It has long been recognized that one of the major differences between solid tumours and adult normal tissues is the pattern and rate of development of the vascular network. New vessel formation in tumours is rapid, but it is insufficient, particularly in a 3-dimensional arrangement , to provide an adequate nutrient supply to all the tumour cells (Hirst et al., 1982). For this reason many tumour cells are non-proliferating because of nutrient deprivation, and hypoxic because of oxygen depletion by the metabolizing tumour cells around each capillary. This produces resistance to both chemotherapy and radiotherapy. A great deal of research is devoted to finding ways of improving the oxygenation, proliferative status and drug delivery in such tumours. recognized the special ability of tumour cells to promote new vessel formation via the tumour angiogenesis factor (TAF). They have proposed methods ofpreventing tumour growth by interfering with angio-genesis, including an immunological technique for inactivating TAF by producing an anti-TAF antibody which would prevent further capillary proliferation. Elsewhere, little attention has been paid to the enormous differential between the proliferation characteristics of the tumour vasculature and the normal tissue vasculature. Tannock (1970), Hirst & Denekamp (1979) and Hirst et al. (1982) have compared the proliferation rate of the capillary endothelium in tumours with that of the tumour cells themselves. They concluded that the rate of endothelial proliferation limits tumour cell production even though as many as 18% of the endothelial cells can be in DNA synthesis at any one time. Other studies have concentrated on the very low proliferation rate of endothelial cells in a variety of normal tissues (see reviews by Tannock & Hayashi, 1972; Hirst et al., 1980). However, the remarkable difference in proliferation rates between endothelium in tumours and in normal tissues does not seem to have been previously commented upon or identified as a potential route for directing therapy at a tumour. The Table summarizes the published labelling index (LI) for normal tissue and tumour endothelium, and illustrates the large difference between them. The values shown were obtained by scoring auto-radiographs …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
(1985) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60946-x · Cited by 1,071
Mechanisms of normal and tumor-derived angiogenesis
Papetti, M., & Herman, I. M. (2002) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00389.2001 · Cited by 809
Siemann, D. W. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.05.001 · Cited by 611
Vascular Targeting Agents as Cancer Therapeutics
Thorpe, P. E. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0642-03 · Cited by 577
Endothelial proliferation in tumours and normal tissues: Continuous labelling studies
Hobson, B., & Denekamp, J. (1984) · British Journal of Cancer · doi:10.1038/bjc.1984.66 · Cited by 565
Self-citationKerbel, R. S. (1991) · BioEssays · doi:10.1002/bies.950130106 · Cited by 441
Liposomal paclitaxel formulations
Koudelka, Š., & Turánek, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.09.006 · Cited by 366
The biology of the combretastatins as tumour vascular targeting agents
TOZER, G. M., KANTHOU, C., PARKINS, C. S., & HILL, S. A. (2002) · International Journal of Experimental Pathology · doi:10.1046/j.1365-2613.2002.00211.x · Cited by 335
Colchicine-Binding Site Inhibitors from Chemistry to Clinic: A Review
McLoughlin, E. C., & O’Boyle, N. M. (2020) · Pharmaceuticals · doi:10.3390/ph13010008 · Cited by 316
Orthotopic models of cancer for preclinical drug evaluation
Bibby, M. C. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.11.021 · Cited by 315
Vascular‐targeting therapies for treatment of malignant disease
Siemann, D. W., Chaplin, D. J., & Horsman, M. R. (2004) · Cancer · doi:10.1002/cncr.20299 · Cited by 310
Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results
Rustin, G. J. S., Galbraith, S. M., Anderson, H., Stratford, M., Folkes, L. K., Sena, L., Gumbrell, L., & Price, P. M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.185 · Cited by 307
Novel Agents on the Horizon for Cancer Therapy
Ma, W. W., & Adjei, A. A. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20003 · Cited by 304
Vascular attack as a therapeutic strategy for cancer
Denekamp, J. (1990) · CANCER AND METASTASIS REVIEW · doi:10.1007/bf00046365 · Cited by 264
Self-citationVascular disrupting agents in clinical development
Hinnen, P., & Eskens, F. A. L. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603694 · Cited by 263
Endothelial-cell proliferation in experimental tumours
Denekamp, J., & Hobson, B. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.263 · Cited by 237
Self-citationThe history of angiogenesis inhibitors
Ribatti, D. (2007) · Leukemia · doi:10.1038/sj.leu.2404756 · Cited by 15
Metadata
- Authors
- Denekamp, J.
- Venue
- British Journal of Cancer
- Published
- 1982-01
- Volume
- 45
- Issue
- 1
- Pages
- 136-139
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2000688337
- Cited by
- 249
- References
- 0
- FWCI
- 2.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.